Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration

被引:5
|
作者
Kaplowitz, Eliana [1 ,2 ]
Truong, Ashley [3 ]
Macmadu, Alexandria [1 ,4 ]
Berk, Justin [4 ,5 ]
Martin, Harrison [1 ,6 ]
Burke, Caroline [7 ]
Rich, Josiah D. [1 ,2 ,5 ,8 ,10 ]
Brinkley-Rubinstein, Lauren [1 ,9 ]
机构
[1] Miriam Hosp, Ctr Hlth Justice Transformat, Providence, RI USA
[2] Rhode Isl Hosp, Ctr Biomed Res Excellence Opioids & Overdose, Providence, RI USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA
[4] Rhode Isl Dept Correct, Cranston, RI USA
[5] Brown Univ, Sch Med, Providence, RI USA
[6] Wesleyan Univ, Smith Coll, Middletown, CT USA
[7] Smith Coll, Northampton, MA USA
[8] Brown Univ Sch Publ Hlth, Dept Epidemiol, Providence, RI USA
[9] Univ North Carolina Chapel Hill, Dept Social Med, Chapel Hill, NC USA
[10] Miriam Hosp, 164 Summit Ave, Providence, RI 02906 USA
关键词
medication for opioid use disorder; treatment retention; incarceration; reentry barriers; METHADONE; PRISON; DEATH; STATE; RISK;
D O I
10.1097/ADM.0000000000001029
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundAlthough the burden of opioid use disorder is disproportionately high among persons who are incarcerated, medications for opioid use disorder are often unavailable in correctional settings. The Rhode Island Department of Corrections provides all 3 classes of medications for opioid use disorder to clinically eligible persons who are incarcerated. Despite a decrease in fatal overdoses among persons with recent criminal legal system involvement since the program's implementation, barriers to continued engagement in treatment after release from incarceration still exist.MethodsWe conducted 40 semistructured, qualitative interviews with people who were incarcerated and enrolled in the comprehensive medications for opioid use disorder program at the Rhode Island Department of Corrections. Analysis applied a general, inductive approach using NVivo 12.ResultsParticipants discussed barriers to treatment engagement before incarceration, as well as anticipated barriers to medications to treat opioid use disorder continuation after release from incarceration. Structural factors including housing, health insurance, transportation, and the treatment program structure, as well as social factors such as social support networks were perceived to influence retention in medications to treat opioid use disorder post-release.ConclusionOur findings suggest that people with opioid use disorder who are incarcerated encounter unique challenges upon community reentry. Addressing structural factors that pose barriers to post-release engagement is essential to sustaining retention. We recommend utilization of peer recovery specialists to alleviate some of the stress of navigating the structural barriers identified by participants.
引用
收藏
页码:54 / 59
页数:6
相关论文
共 50 条
  • [21] Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care
    Tofighi, Babak
    Williams, Arthur Robin
    Chemi, Chemi
    Sindhu, Selena
    Dickson, Vicky
    Lee, Joshua D.
    [J]. SUBSTANCE USE & MISUSE, 2019, 54 (14) : 2409 - 2419
  • [22] Breastfeeding Motivators and Barriers in Women Receiving Medications for Opioid Use Disorder
    Yonke, Nicole
    Yakes Jimenez, Elizabeth
    Leeman, Lawrence
    Leyva, Yuridia
    Ortega, Alyssa
    Bakhireva, Ludmila N.
    [J]. BREASTFEEDING MEDICINE, 2020, 15 (01) : 17 - 23
  • [23] Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain
    Chapman, Susan A.
    Fraimow-Wong, Leah
    Phoenix, Bethany J.
    Tierney, Matthew
    Spetz, Joanne
    [J]. JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 157
  • [24] Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam
    King, Caroline
    Cook, Ryan
    Giang, Le Minh
    Bart, Gavin
    Hoffman, Kim
    Waddell, Elizabeth Needham
    Korthuis, P. Todd
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2022, 134
  • [25] Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
    Abraham, Amanda J.
    Andrews, Christina M.
    Harris, Samantha J.
    Friedmann, Peter D.
    [J]. NEUROTHERAPEUTICS, 2020, 17 (01) : 55 - 69
  • [26] Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
    Amanda J. Abraham
    Christina M. Andrews
    Samantha J. Harris
    Peter D. Friedmann
    [J]. Neurotherapeutics, 2020, 17 : 55 - 69
  • [27] Outcomes Associated with Treatment with and Without Medications for Opioid Use Disorder
    Ryan Mutter
    Donna Spencer
    Jeffrey McPheeters
    [J]. The Journal of Behavioral Health Services & Research, 2023, 50 : 524 - 539
  • [28] Outcomes Associated with Treatment with and Without Medications for Opioid Use Disorder
    Mutter, Ryan
    Spencer, Donna
    McPheeters, Jeffrey
    [J]. JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH, 2023, 50 (04): : 524 - 539
  • [29] Extended-release naltrexone for opioid use disorder started during or following incarceration
    Lincoln, Thomas
    Johnson, Benjamin D.
    McCarthy, Patrick
    Alexander, Ellen
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 : 97 - 100
  • [30] A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System
    Grella, Christine E.
    Ostile, Erika
    Scott, Christy K.
    Dennis, Michael
    Carnavale, John
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 81